Tradestie Institutional Equity Comparison Engine

NKTR vs MLTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MLTX Overall Edge

MLTX Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while NKTR counters with relative strength in Valuation. Fundamentally, NKTR trades at 34.0x Forward P/E with -239.3% operating margin (-9.3% YoY revenue) versus MLTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NKTR sits in BREAKDOWN (5th %ile IV; Dealer Gamma Walls on Pro) against MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner NKTR
NKTR 34.0x vs MLTX N/M Fwd P/E
Growth & Margin Winner MLTX
Op Margin -239.3% vs 0.0% ยท YoY -9.3% vs +0.0%
Momentum & Technical Winner MLTX
1Y -32.2% vs -5.7% ยท 52W Pos 4% vs 17%
Options & Structure Winner MLTX
BREAKDOWN (5th %ile IV) vs BREAKDOWN (7th %ile IV)
NKTR NASDAQ
Nektar Therapeutics
Pharmaceutical Preparations
$36.57
-1.88% 1D
Market Cap $1.3B
1M Return +2.21%
1Y Return -32.22%
Forward P/E 34.0x
Unified AI Score
61.1 / 100 BUY
Tech 47.0 Fund 58.0 Flow 67.0 Mom 60.0
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
1M Return +24.08%
1Y Return -5.65%
Forward P/E N/M
Unified AI Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NKTR -32.22% MLTX -5.65% Spread: +26.57 pp (MLTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NKTR TTM Op. Margin: -239.3% MLTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NKTR vs MLTX. Trailing 12-month operating profitability (NKTR -239.3% vs MLTX 0.0%) and valuation multiples (NKTR 34.0x vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NKTR (6) vs MLTX (4)
Institutional Metric NKTR MLTX Criterion Row Winner
Market Capitalization Scale $1.3B $1.1B Larger Scale NKTR
Trailing P/E Ratio Valuation 34.0x N/M Lower Multiple NKTR
Forward P/E Ratio Valuation 34.0x N/M Lower Multiple NKTR
Revenue Growth (YoY) Growth -9.3% +0.0% Higher Growth MLTX
Operating Margin (TTM) Profitability -239.3% 0.0% Higher Margin MLTX
Net Profit Margin Profitability -287.8% 0.0% Higher Margin MLTX
Return on Equity (ROE) Capital Efficiency -35.8% -81.5% Higher ROE NKTR
52-Week Range Position Momentum 4% ($33โ€“$109) 17% ($9โ€“$23) Stronger Trend MLTX
Beta / 30D Volatility Risk Regime 1.10ฮฒ ยท 48% Vol 1.61ฮฒ ยท 90% Vol Lower Realized Risk NKTR
Unified Institutional Score Composite Signal 61.1 / 100 (BUY) 38.3 / 100 (SELL) Higher Composite NKTR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NKTR vs MLTX Buy Guide
NKTR BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live NKTR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MLTX BREAKDOWN
103d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live MLTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NKTR nor MLTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.